Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance

Strizki, J. M., Gaspar, J. M., Howe, J. A., Hutchins, B., Mohri, H., Nair, M. S., Kinek, K. C., McKenna, P., Goh, S. L., & Murgolo, N. (2024). Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance. Antimicrobial Agents and Chemotherapy, 68(1). https://doi.org/10.1128/aac.00953-23
Authors:
Julie Strizki
John M. Gaspar
John A. Howe
Beth Hutchins
Hiroshi Mohri
Manoj S. Nair
Keith C. Kinek
Philip M. McKenna
Shih Lin Goh
Nicholas Murgolo
Affiliated Authors:
Hiroshi Mohri
Manoj S. Nair
Columbia Affiliation:
Author Keywords:
antiviral resistance
covid-19
molnupiravir
n-hydroxycytidine
Publication Type:
Article
Unique ID:
10.1128/aac.00953-23
PMID:
Publication Date:
Data Source:
OpenAlex

Record Created: